Eisai's commitment to innovative solutions in disease prevention, treatment and care
for the health and well being of people worldwide is embodied in our human health
care (hhc) mission. human health care (hhc) means we give first thoughts to patients
and their families by helping to ensure access to necessary medicines.
On this site you will find information related to coding, coverage and reimbursement for select
Eisai products and information about Patient Assistance Programs which may be available
to patients in need.
Fycompa® (perampanel) is indicated as adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy aged 12 years and older.
Hostility- and aggression-related adverse reactions occurred in 12% and 20% of clinical trial patients randomized to receive Fycompa® at doses of 8 mg and 12 mg/day, respectively, compared to 6% of patients in the placebo group. These effects were dose-related and generally appeared within the first 6 weeks of treatment, although new events continued to be observed through more than 37 weeks. These effects in Fycompa®-treated patients led to dose reduction, interruption, and discontinuation more frequently than placebo-treated patients. The combination of alcohol and Fycompa® significantly worsened mood and increased anger. Patients taking Fycompa® should avoid the use of alcohol. Patients, their caregivers, and families should be informed that Fycompa® may increase the risk of psychiatric events. Patients should be monitored during treatment and for at least one month after the last dose of Fycompa®, and especially when taking higher doses and during the initial few weeks of drug therapy (titration period) or at other times of dose increases.
Antiepileptic drugs (AEDs), including Fycompa®, increase the risk of suicidal thoughts or behavior in patients. Anyone considering prescribing Fycompa® or any other AED must balance the risk of suicidal thoughts or behavior with the risk of untreated illness. Epilepsy and many other illnesses for which AEDs are prescribed are themselves associated with morbidity and mortality and an increased risk of suicidal thoughts and behavior. Patients, their caregivers, and families should be informed of the risk and advised to monitor and immediately report the emergence or worsening of depression, suicidal thoughts or behavior, thoughts about self-harm, and/or any unusual changes in mood or behavior. Should suicidal thoughts or behavior emerge during treatment, consider whether the emergence of these symptoms in any given patient may be related to the illness being treated.
Fycompa® caused dose-related increases in events related to dizziness and disturbance in gait or coordination. Dizziness and vertigo were reported in 35% and 47% of patients randomized to receive Fycompa® at doses of 8 mg and 12 mg/day, respectively, compared to 10% of placebo-treated patients. Gait disturbance related events were reported in 12% and 16% of patients randomized to receive Fycompa® at doses of 8 mg and 12 mg/day, respectively, compared to 2% of placebo-treated patients. These adverse reactions occurred mostly during the titration phase.
Fycompa® caused dose-dependent increases in somnolence and fatigue-related events. Somnolence was reported in 16% and 18% of patients randomized to receive Fycompa® at doses of 8 mg and 12 mg/day, respectively, compared to 7% of placebo patients. Fatigue-related events were reported in 12% and 15% of patients randomized to receive Fycompa® at doses of 8 mg and 12 mg/day, respectively, compared to 5% of placebo patients. In the controlled Phase 3 epilepsy clinical trials, these adverse reactions occurred mostly during the titration phase. Patients should be advised against engaging in hazardous activities requiring mental alertness, such as operating motor vehicles or dangerous machinery, until the effect of Fycompa® is known.
Falls were reported in 5% and 10% of patients randomized to receive Fycompa® at doses of 8 mg and 12 mg/day, respectively, compared to 3% of placebo-treated patients.
A gradual withdrawal is generally recommended with antiepileptic drugs to minimize the potential of increased seizure frequency.
In clinical trials, the most frequently reported dose-related adverse reactions in patients receiving Fycompa® 8 mg or 12 mg vs placebo (>e;4% and at least 1% higher than the placebo group) included dizziness (36% vs 9%), somnolence (16% vs 7%), fatigue (10% vs 5%), irritability (9% vs 3%), falls (7% vs 3%), nausea (7% vs 5%), ataxia (5% vs 0%), balance disorder (4% vs 1%), gait disturbance (4% vs 1%), vertigo (4% vs 1%), and weight gain (4% vs 1%).
Fycompa® may decrease the efficacy of contraceptives containing levonorgestrel. Plasma levels of Fycompa® were decreased when administered with carbamazepine, phenytoin and oxcarbazepine. Concomitant use with strong CYP3A inducers such as St. John’s wort and rifampin should be avoided. Multiple dosing of Fycompa® 12 mg/day enhanced the effects of alcohol on vigilance and alertness, and increased levels of anger, confusion, and depression. These effects may also be seen when Fycompa® is used in combination with other CNS depressants.
Fycompa® should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Physicians are advised to recommend that pregnant patients taking Fycompa® enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry. Caution should be exercised when Fycompa® is administered to a nursing woman.
Use in patients with severe hepatic or severe renal impairment is not recommended. Dosage adjustments are recommended in patients with mild or moderate hepatic impairment. Use with caution in patients with moderate renal impairment.
Fycompa® is a Schedule III controlled drug substance and has the potential to be abused or lead to drug dependence.
For more information about Fycompa® please see Prescribing Information.
HEXALEN® (altretamine) is indicated for use as a single
agent in the palliative treatment of patients
with persistent or recurrent ovarian cancer following first-line therapy with a cisplatin and/or alkylating agent-based
Eisai cannot guarantee payment of any claim. Coding, coverage, and reimbursement may vary significantly by payor, plan, patient, and setting of care. Actual coverage and reimbursement decisions are made by individual payors following the receipt of claims. For additional information, customers should consult with their payors for all relevant coding, reimbursement, and coverage requirements. It is the sole responsibility of the provider to select the proper code and ensure the accuracy of all claims used in seeking reimbursement. All services must be medically appropriate and properly supported in the patient medical record.
This information is intended for use by our healthcare professionals in the United States only. Eisai Inc. recognizes the Internet is a global communications medium; however, laws, regulatory requirements and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here is not appropriate for use outside the United States. This site contains information about products that may have different product labeling in different countries.
CORP0485 ©2015 – Eisai Inc. All rights reserved.
This site was last modified on : Febuary 18, 2015 at 10:45 am ET